New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:07 EDTISRIsoRay announces first human prostate implant using Cesium-131 isotope seeds
IsoRay announced the first prostate cancer implant combining IsoRay's Cesium-131 seeds with C4 Imaging's Sirius positive signal MRI markers. IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging's innovative positive signal MRI markers in the treatment of prostate cancer. By combining two of the newest technologies available in brachytherapy, we hope to demonstrate superior outcomes with the goal of improving patient lives. As we continue to develop our product offerings both internally and in partnership with other industry leaders, our message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients."
News For ISR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:37 EDTISRIsoRay selected by Chicago prostate cancer center for use in study
IsoRay announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy. Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.
June 23, 2015
08:37 EDTISRIsoRay intends to 'vigorously' defend litigation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use